
Estela Rodriguez/doctors.umiamihealth.org
Jun 24, 2025, 10:34
Estela Rodriguez: FDA Grants Accelerated Approval to Dato-Dxd for Previously Treated EGFR+ NSCLC
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, shared a post on X:
“Happy Monday!
FDA Oncology grants accelerated approval to Dato-Dxd datopotamab deruxtecan (Trop-2 ADC) for previously treated EGFR+ NSCLC based on TROPION Lung01, 05
ORR of 42.7%, mDoR 7.0 mos
mOS 15.6 mos
AEs: Nausea, stomatitis, ILD.”
More posts featuring Estela Rodriguez.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 24, 2025, 10:32
Jun 24, 2025, 09:37
Jun 24, 2025, 09:29
Jun 24, 2025, 09:26